Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.
His team will describe the approach in one of nearly 11,000 presentations at the 249th National Meeting & Exposition of the American Chemical Society (ACS).
If a tumor is present in a prostate biopsy, a pathologist grades its aggressiveness on a scale known as the Gleason Grading System. Tumors with Gleason scores of 7 and above are considered aggressive and likely to spread, requiring surgical removal of the prostate gland (prostatectomy) or radiation therapy. In contrast, prostate tumors with Gleason scores of 6 and below are less aggressive, and in some cases may cause no symptoms or health problems for the duration of the man's life.
In cases of low-grade prostate cancer, many urologists do not treat the disease, but instead do what's called "active surveillance," says Bruce Hollis, Ph.D., who is at the Medical University of South Carolina. "The cure—meaning surgery or radiation—is probably worse than the disease, so they wait a year and then do another biopsy to see where the patient stands."
However, knowing that they have even low-grade prostate cancer can cause patients and their families excessive anxiety, which prompts some of the men to undergo an elective prostatectomy, despite the risk of complications such as infection, urinary incontinence and erectile dysfunction. But a man must wait 60 days from the time of his biopsy before he can undergo a prostatectomy, so that inflammation from the biopsy can subside.
Hollis wondered if giving these men vitamin D supplements during the 60-day waiting period would affect their prostate cancer. His previous research had shown that when men with low-grade prostate cancer took vitamin D supplements for a year, 55 percent of them showed decreased Gleason scores or even complete disappearance of their tumors compared to their biopsies a year before (J. Clin. Endocrinol. Metab., 2012, DOI: 10.1210/jc.2012-1451).
In a new randomized, controlled clinical trial, his team assigned 37 men undergoing elective prostatectomies either to a group that received 4,000 U of vitamin D per day, or to a placebo group that didn't receive vitamin D. The men's prostate glands were removed and examined 60 days later.
Preliminary results from this study indicate that many of the men who received vitamin D showed improvements in their prostate tumors, whereas the tumors in the placebo group either stayed the same or got worse. Also, vitamin D caused dramatic changes in the expression levels of many cell lipids and proteins, particularly those involved in inflammation. "Cancer is associated with inflammation, especially in the prostate gland," says Hollis. "Vitamin D is really fighting this inflammation within the gland."
The protein most strongly induced by vitamin D was one called growth differentiation factor 15 (GDF15). Previous studies by other groups showed that GDF15 dials down inflammation, and many aggressive prostate cancers make little or no GDF15.
The new research suggests that vitamin D supplementation may improve low-grade prostate cancers by reducing inflammation, perhaps lessening the need for eventual surgery or radiation treatment. "We don't know yet whether vitamin D treats or prevents prostate cancer," says Hollis. "At the minimum, what it may do is keep lower-grade prostate cancers from going ballistic."
Hollis notes that the dosage of vitamin D administered in the study—4,000 U—is well below the 10,000-20,000 U that the human body can make from daily sun exposure. "We're treating these guys with normal body levels of vitamin D," he says. "We haven't even moved into the pharmacological levels yet."
Explore further: Vitamin D deficiency linked to aggressive prostate cancer
More information: Vitamin D in the prevention and treatment of cancer, 249th National Meeting & Exposition of the American Chemical Society (ACS).
Abstract
Vitamin D is metabolized, activated and acts through the vitamin D receptor expressed in a variety of human tissues, including cancer tissue of various origin. Basic research has revealed that vitamin D has anti-cancer potentials including pro-differentiation, anti-proliferation, and anti-inflammatory, to name a few. Epidemiological studies have revealed that low circulating 25(OH)D levels are a risk factor for a variety of human cancers. However, clinical results have been lacking. I will present here our recent clinical trials into human prostate cancer and how supplementing vitamin D3 can have profound influence on disease progression as well as its ability to modify molecular and biochemical pathways.
Medical Xpress on facebook
Related Stories
Vitamin D deficiency linked to aggressive prostate cancer
May 01, 2014
African-American and European-American men at high risk of prostate cancer have greater odds of being diagnosed with an aggressive form of the disease if they have a vitamin D deficiency, according to a new study from Northwestern ...
Molecules in prostate tumors might predict whether RT can help prevent recurrence
Mar 11, 2015
A new study has identified a group of molecules in prostate-cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate ...
No link found between vitamin D level and fatal prostate cancer
Mar 10, 2015
(HealthDay)—Neither circulating 25-hydroxyvitamin D (25[OH]D) levels nor common variations in vitamin D pathway genes appear to be associated with risk of fatal prostate cancer, according to research published ...
Finally: A missing link between vitamin D and prostate cancer
Oct 22, 2014
A University of Colorado Cancer Center study recently published in the journal Prostate offers compelling evidence that inflammation may be the link between Vitamin D and prostate cancer. Specifically, the st ...
Watchful waiting isn't right for everyone
Sep 08, 2014
There is an active controversy among oncologists about when to treat prostate cancer patients, with some suggesting that the word "cancer" be removed from the description of low grade disease, in order to prevent overtreatment. ...
Recommended for you
Popular weed killer deemed probable carcinogen by UN
Mar 20, 2015
One of the world's most popular weed-killers—and the most widely used kind in the U.S.—has been labeled a probable carcinogen by the International Agency for Research on Cancer.
Researchers combat prostate cancer at cellular level
Mar 20, 2015
Florida International University scientists are battling prostate cancer at the cellular level. Researchers from FIU's Biomolecular Sciences Institute (BSI) believe they can eradicate prostate cancer that returns in patients who wer ...
Researchers ID potential prognostic marker for recurrence of head and neck squamous cell carcinoma
Mar 20, 2015
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated ...
Skin cancer rates rise for hispanic, asian women
Mar 20, 2015
(HealthDay)—While most white people who develop skin cancer are older men, the reverse is true in Asian and Hispanic populations, a new study suggests.
Breastfeeding may offset leukemia risk
Mar 20, 2015
Breastfeeding could help reduce the risk of acute lymphoblastic leukemia in children, according to a WA-led study.
Novel therapy to treat patients with hereditary breast cancer and ovarian cancer
Mar 20, 2015
European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.
His team will describe the approach in one of nearly 11,000 presentations at the 249th National Meeting & Exposition of the American Chemical Society (ACS).
If a tumor is present in a prostate biopsy, a pathologist grades its aggressiveness on a scale known as the Gleason Grading System. Tumors with Gleason scores of 7 and above are considered aggressive and likely to spread, requiring surgical removal of the prostate gland (prostatectomy) or radiation therapy. In contrast, prostate tumors with Gleason scores of 6 and below are less aggressive, and in some cases may cause no symptoms or health problems for the duration of the man's life.
In cases of low-grade prostate cancer, many urologists do not treat the disease, but instead do what's called "active surveillance," says Bruce Hollis, Ph.D., who is at the Medical University of South Carolina. "The cure—meaning surgery or radiation—is probably worse than the disease, so they wait a year and then do another biopsy to see where the patient stands."
However, knowing that they have even low-grade prostate cancer can cause patients and their families excessive anxiety, which prompts some of the men to undergo an elective prostatectomy, despite the risk of complications such as infection, urinary incontinence and erectile dysfunction. But a man must wait 60 days from the time of his biopsy before he can undergo a prostatectomy, so that inflammation from the biopsy can subside.
Hollis wondered if giving these men vitamin D supplements during the 60-day waiting period would affect their prostate cancer. His previous research had shown that when men with low-grade prostate cancer took vitamin D supplements for a year, 55 percent of them showed decreased Gleason scores or even complete disappearance of their tumors compared to their biopsies a year before (J. Clin. Endocrinol. Metab., 2012, DOI: 10.1210/jc.2012-1451).
In a new randomized, controlled clinical trial, his team assigned 37 men undergoing elective prostatectomies either to a group that received 4,000 U of vitamin D per day, or to a placebo group that didn't receive vitamin D. The men's prostate glands were removed and examined 60 days later.
Preliminary results from this study indicate that many of the men who received vitamin D showed improvements in their prostate tumors, whereas the tumors in the placebo group either stayed the same or got worse. Also, vitamin D caused dramatic changes in the expression levels of many cell lipids and proteins, particularly those involved in inflammation. "Cancer is associated with inflammation, especially in the prostate gland," says Hollis. "Vitamin D is really fighting this inflammation within the gland."
The protein most strongly induced by vitamin D was one called growth differentiation factor 15 (GDF15). Previous studies by other groups showed that GDF15 dials down inflammation, and many aggressive prostate cancers make little or no GDF15.
The new research suggests that vitamin D supplementation may improve low-grade prostate cancers by reducing inflammation, perhaps lessening the need for eventual surgery or radiation treatment. "We don't know yet whether vitamin D treats or prevents prostate cancer," says Hollis. "At the minimum, what it may do is keep lower-grade prostate cancers from going ballistic."
Hollis notes that the dosage of vitamin D administered in the study—4,000 U—is well below the 10,000-20,000 U that the human body can make from daily sun exposure. "We're treating these guys with normal body levels of vitamin D," he says. "We haven't even moved into the pharmacological levels yet."
Explore further: Vitamin D deficiency linked to aggressive prostate cancer
More information: Vitamin D in the prevention and treatment of cancer, 249th National Meeting & Exposition of the American Chemical Society (ACS).
Abstract
Vitamin D is metabolized, activated and acts through the vitamin D receptor expressed in a variety of human tissues, including cancer tissue of various origin. Basic research has revealed that vitamin D has anti-cancer potentials including pro-differentiation, anti-proliferation, and anti-inflammatory, to name a few. Epidemiological studies have revealed that low circulating 25(OH)D levels are a risk factor for a variety of human cancers. However, clinical results have been lacking. I will present here our recent clinical trials into human prostate cancer and how supplementing vitamin D3 can have profound influence on disease progression as well as its ability to modify molecular and biochemical pathways.
Medical Xpress on facebook
Related Stories
Vitamin D deficiency linked to aggressive prostate cancer
May 01, 2014
African-American and European-American men at high risk of prostate cancer have greater odds of being diagnosed with an aggressive form of the disease if they have a vitamin D deficiency, according to a new study from Northwestern ...
Molecules in prostate tumors might predict whether RT can help prevent recurrence
Mar 11, 2015
A new study has identified a group of molecules in prostate-cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate ...
No link found between vitamin D level and fatal prostate cancer
Mar 10, 2015
(HealthDay)—Neither circulating 25-hydroxyvitamin D (25[OH]D) levels nor common variations in vitamin D pathway genes appear to be associated with risk of fatal prostate cancer, according to research published ...
Finally: A missing link between vitamin D and prostate cancer
Oct 22, 2014
A University of Colorado Cancer Center study recently published in the journal Prostate offers compelling evidence that inflammation may be the link between Vitamin D and prostate cancer. Specifically, the st ...
Watchful waiting isn't right for everyone
Sep 08, 2014
There is an active controversy among oncologists about when to treat prostate cancer patients, with some suggesting that the word "cancer" be removed from the description of low grade disease, in order to prevent overtreatment. ...
Recommended for you
Popular weed killer deemed probable carcinogen by UN
Mar 20, 2015
One of the world's most popular weed-killers—and the most widely used kind in the U.S.—has been labeled a probable carcinogen by the International Agency for Research on Cancer.
Researchers combat prostate cancer at cellular level
Mar 20, 2015
Florida International University scientists are battling prostate cancer at the cellular level. Researchers from FIU's Biomolecular Sciences Institute (BSI) believe they can eradicate prostate cancer that returns in patients who wer ...
Researchers ID potential prognostic marker for recurrence of head and neck squamous cell carcinoma
Mar 20, 2015
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated ...
Skin cancer rates rise for hispanic, asian women
Mar 20, 2015
(HealthDay)—While most white people who develop skin cancer are older men, the reverse is true in Asian and Hispanic populations, a new study suggests.
Breastfeeding may offset leukemia risk
Mar 20, 2015
Breastfeeding could help reduce the risk of acute lymphoblastic leukemia in children, according to a WA-led study.
Novel therapy to treat patients with hereditary breast cancer and ovarian cancer
Mar 20, 2015
European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment